A review of Trop-2 drugs for HER2-negative breast cancer
Original title: Progress of Trop-2-targeted antibody-drug conjugates in HER-2-negative breast cancer: a mini-review.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This looks across many earlier studies rather than running a new one.
This is a summary of where the research is going, not a new result.
The short version
This is a summary of where research stands on a group of breast cancer drugs that aim at a marker called Trop-2.
What was studied. This is a short review article. The authors gathered what is known about Trop-2 targeted antibody-drug conjugates in breast cancer that is HER2-negative. The drugs covered include sacituzumab govitecan, sacituzumab tirumotecan, and datopotamab deruxtecan.
What they found. These drugs carry a cancer-killing medicine straight to tumor cells that show Trop-2. The authors report that sacituzumab govitecan worked well in triple-negative breast cancer and in hormone receptor-positive, HER2-negative breast cancer, with side effects people could tolerate. They also review how these drugs did in people whose cancer had spread to the brain, and they say many questions are still open.
What this means, and what it doesn't
What it could mean: If you have HER2-negative breast cancer, this is an active area of study. Some of these drugs are being tested in trials right now. Your cancer team can tell you whether any of this fits your own situation.
What it doesn't mean: This is a review of other people's work, not a new study. It does not report new results from patients. It does not tell you that any of these drugs will help you. It is not a cure and it is not a promise. This work is about breast cancer, including cancer that has spread to the brain. It is not about a tumor that starts in the brain.
Source: PubMed, April 30, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.